Literature DB >> 16894342

Antiangiogenic therapies in endometriosis.

S Ferrero1, N Ragni, V Remorgida.   

Abstract

Oral contraceptives, androgenic agents, progestins and gonadotropin-releasing hormone analogues have all been successfully used in the treatment of endometriosis. However, none of these drugs can eradicate the disease. It is widely accepted that the growth of newly formed blood vessels is essential for the establishment and growth of endometriotic lesions; therefore, inhibition of angiogenesis may offer a new option for treatment of this disorder. In this paper, we reviewed anti-vascular endothelial growth factor agents and other angiostatic drugs (i.e., TNP470, endostatin, anginex, rapamycin) that have been studied in laboratory and animal models of endometriosis. Although preliminary results are interesting, further investigations are required before clinical trials can be planned in humans. Published online 7 August 2006.

Entities:  

Mesh:

Year:  2006        PMID: 16894342      PMCID: PMC2013795          DOI: 10.1038/sj.bjp.0706860

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  In vivo analysis of angiogenesis in endometriosis-like lesions by intravital fluorescence microscopy.

Authors:  Matthias W Laschke; Antje Elitzsch; Brigitte Vollmar; Michael D Menger
Journal:  Fertil Steril       Date:  2005-10       Impact factor: 7.329

Review 2.  Future perspectives in the medical treatment of endometriosis.

Authors:  Simone Ferrero; Luiza Helena Abbamonte; Paola Anserini; Valentino Remorgida; Nicola Ragni
Journal:  Obstet Gynecol Surv       Date:  2005-12       Impact factor: 2.347

3.  Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model.

Authors:  Christian M Becker; David A Sampson; Sarah M Short; Kashi Javaherian; Judah Folkman; Robert J D'Amato
Journal:  Fertil Steril       Date:  2006-01       Impact factor: 7.329

4.  Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation.

Authors:  M W Laschke; A Elitzsch; C Scheuer; J H Holstein; B Vollmar; M D Menger
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

5.  Endostatin inhibits the growth of endometriotic lesions but does not affect fertility.

Authors:  Christian M Becker; David A Sampson; Maria A Rupnick; Richard M Rohan; Jason A Efstathiou; Sarah M Short; George A Taylor; Judah Folkman; Robert J D'Amato
Journal:  Fertil Steril       Date:  2005-10       Impact factor: 7.329

6.  Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.

Authors:  V C McAlister; K M Peltekian; D A Malatjalian; S Colohan; S MacDonald; H Bitter-Suermann; A S MacDonald
Journal:  Liver Transpl       Date:  2001-08       Impact factor: 5.799

Review 7.  Sirolimus: its role in nephrology.

Authors:  Vincent Ws Lee; Jeremy R Chapman
Journal:  Nephrology (Carlton)       Date:  2005-12       Impact factor: 2.506

8.  Antiangiogenesis therapy for endometriosis.

Authors:  Annemiek W Nap; Arjan W Griffioen; Gerard A J Dunselman; Jessica C A Bouma-Ter Steege; Victor L J L Thijssen; Johannes L H Evers; Patrick G Groothuis
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

9.  Antiangiogenic agents are effective inhibitors of endometriosis.

Authors:  M Louise Hull; D Stephen Charnock-Jones; Clement L K Chan; Kaylon L Bruner-Tran; Kevin G Osteen; Brian D M Tom; Tai-Ping D Fan; Stephen K Smith
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  Fibrosis and smooth muscle metaplasia in rectovaginal endometriosis.

Authors:  Tomoko Itoga; Toshiharu Matsumoto; Hiroyuki Takeuchi; Shigetaka Yamasaki; Noriko Sasahara; Tanji Hoshi; Katsuyuki Kinoshita
Journal:  Pathol Int       Date:  2003-06       Impact factor: 2.534

View more
  6 in total

Review 1.  Pharmacological treatment of endometriosis: experience with aromatase inhibitors.

Authors:  Simone Ferrero; Pier L Venturini; Nicola Ragni; Giovanni Camerini; Valentino Remorgida
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

2.  Slit2 overexpression results in increased microvessel density and lesion size in mice with induced endometriosis.

Authors:  Sun-Wei Guo; Yu Zheng; Yuan Lu; Xishi Liu; Jian-Guo Geng
Journal:  Reprod Sci       Date:  2012-08-08       Impact factor: 3.060

Review 3.  Novel therapies targeting endometriosis.

Authors:  Hugh S Taylor; Kevin G Osteen; Kaylon L Bruner-Tran; Charles J Lockwood; Graciela Krikun; Anna Sokalska; Antoni J Duleba
Journal:  Reprod Sci       Date:  2011-06-21       Impact factor: 3.060

4.  Adenoviral vector encoding soluble Flt-1 engineered human endometrial mesenchymal stem cells effectively regress endometriotic lesions in NOD/SCID mice.

Authors:  A R Koippallil Gopalakrishnan; H Pandit; S M Metkari; N Warty; T Madan
Journal:  Gene Ther       Date:  2016-03-18       Impact factor: 5.250

Review 5.  Power of proteomics in linking oxidative stress and female infertility.

Authors:  Sajal Gupta; Jana Ghulmiyyah; Rakesh Sharma; Jacques Halabi; Ashok Agarwal
Journal:  Biomed Res Int       Date:  2014-05-12       Impact factor: 3.411

6.  Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate.

Authors:  Amy D DiVasta; Catherine Stamoulis; Jenny Sadler Gallagher; Marc R Laufer; Raymond Anchan; Mark D Hornstein
Journal:  F S Rep       Date:  2021-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.